Aclaris Therapeutics, Inc. (ACRS)
USD 1.27
(6.3%)
USD 1.27
(6.3%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 197.4 Million USD | -22.46% |
| 2022 | 254.59 Million USD | 1.35% |
| 2021 | 251.21 Million USD | 254.9% |
| 2020 | 70.78 Million USD | -27.99% |
| 2019 | 98.29 Million USD | -64.33% |
| 2018 | 275.56 Million USD | 13.16% |
| 2017 | 243.5 Million USD | 38.29% |
| 2016 | 176.08 Million USD | 87.17% |
| 2015 | 94.07 Million USD | 441.38% |
| 2014 | 17.37 Million USD | 22.31% |
| 2013 | 14.2 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 174.06 Million USD | -11.82% |
| 2024 Q2 | 161.07 Million USD | -7.47% |
| 2023 Q3 | 218.35 Million USD | -7.34% |
| 2023 Q4 | 197.4 Million USD | -9.59% |
| 2023 Q1 | 229.7 Million USD | -9.78% |
| 2023 Q2 | 235.64 Million USD | 2.59% |
| 2023 FY | 197.4 Million USD | -22.46% |
| 2022 Q1 | 226.52 Million USD | -9.83% |
| 2022 FY | 254.59 Million USD | 1.35% |
| 2022 Q4 | 254.59 Million USD | -4.87% |
| 2022 Q3 | 267.63 Million USD | -3.72% |
| 2022 Q2 | 277.97 Million USD | 22.71% |
| 2021 Q4 | 251.21 Million USD | -4.66% |
| 2021 Q1 | 161.39 Million USD | 128.02% |
| 2021 Q2 | 288.04 Million USD | 78.47% |
| 2021 FY | 251.21 Million USD | 254.9% |
| 2021 Q3 | 263.49 Million USD | -8.52% |
| 2020 Q4 | 70.78 Million USD | -1.55% |
| 2020 FY | 70.78 Million USD | -27.99% |
| 2020 Q3 | 71.9 Million USD | -15.41% |
| 2020 Q2 | 84.99 Million USD | -12.2% |
| 2020 Q1 | 96.81 Million USD | -1.51% |
| 2019 Q3 | 160.41 Million USD | -26.16% |
| 2019 Q2 | 217.23 Million USD | -14.2% |
| 2019 Q1 | 253.18 Million USD | -8.12% |
| 2019 FY | 98.29 Million USD | -64.33% |
| 2019 Q4 | 98.29 Million USD | -38.72% |
| 2018 Q3 | 176.17 Million USD | -12.71% |
| 2018 Q2 | 201.81 Million USD | -8.52% |
| 2018 Q1 | 220.62 Million USD | -9.4% |
| 2018 FY | 275.56 Million USD | 13.16% |
| 2018 Q4 | 275.56 Million USD | 56.42% |
| 2017 FY | 243.5 Million USD | 38.29% |
| 2017 Q1 | 166.21 Million USD | -5.61% |
| 2017 Q4 | 243.5 Million USD | -6.84% |
| 2017 Q3 | 261.39 Million USD | 47.84% |
| 2017 Q2 | 176.8 Million USD | 6.38% |
| 2016 Q3 | 86.07 Million USD | -10.43% |
| 2016 Q4 | 176.08 Million USD | 104.58% |
| 2016 FY | 176.08 Million USD | 87.17% |
| 2016 Q2 | 96.09 Million USD | 10.11% |
| 2016 Q1 | 87.27 Million USD | -7.23% |
| 2015 Q2 | 12.22 Million USD | 0.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 Q3 | 42.08 Million USD | 244.33% |
| 2015 FY | 94.07 Million USD | 441.38% |
| 2015 Q4 | 94.07 Million USD | 123.53% |
| 2014 FY | 17.37 Million USD | 22.31% |
| 2014 Q4 | 17.37 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 FY | 14.2 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Applied DNA Sciences, Inc. | 13.65 Million USD | -1346.023% |
| Aspira Women's Health Inc. | 6.26 Million USD | -3052.427% |
| Biodesix, Inc. | 99.09 Million USD | -99.206% |
| BioNexus Gene Lab Corp. | 11.39 Million USD | -1631.654% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -2301.067% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -2301.067% |
| Bionano Genomics, Inc. | 214.4 Million USD | 7.928% |
| CareDx, Inc | 484.61 Million USD | 59.266% |
| Check-Cap Ltd. | 25.01 Million USD | -689.083% |
| Castle Biosciences, Inc. | 477.81 Million USD | 58.686% |
| DarioHealth Corp. | 96.38 Million USD | -104.8% |
| Exact Sciences Corporation | 6.47 Billion USD | 96.95% |
| Fulgent Genetics, Inc. | 1.27 Billion USD | 84.494% |
| Guardant Health, Inc. | 1.78 Billion USD | 88.95% |
| ICON Public Limited Company | 16.98 Billion USD | 98.838% |
| IDEXX Laboratories, Inc. | 3.25 Billion USD | 93.944% |
| Illumina, Inc. | 10.11 Billion USD | 98.048% |
| Intelligent Bio Solutions Inc. | 13.77 Million USD | -1332.665% |
| iSpecimen Inc. | 15.81 Million USD | -1147.887% |
| Standard BioTools Inc. | 323.06 Million USD | 38.897% |
| MDxHealth SA | 129.13 Million USD | -52.871% |
| 23andMe Holding Co. | 395.16 Million USD | 50.045% |
| Medpace Holdings, Inc. | 1.65 Billion USD | 88.085% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 83.532% |
| Mainz Biomed B.V. | 15.4 Million USD | -1181.1% |
| ENDRA Life Sciences Inc. | 6.75 Million USD | -2822.723% |
| NeoGenomics, Inc. | 1.68 Billion USD | 88.258% |
| Neogen Corporation | 4.58 Billion USD | 95.694% |
| Inotiv, Inc. | 856.53 Million USD | 76.953% |
| Natera, Inc. | 1.45 Billion USD | 86.452% |
| OpGen, Inc. | 1.88 Million USD | -10387.58% |
| OPKO Health, Inc. | 2.01 Billion USD | 90.187% |
| Psychemedics Corporation | 13.27 Million USD | -1387.604% |
| Prenetics Global Limited | 254.17 Million USD | 22.334% |
| Prenetics Global Limited | 254.17 Million USD | 22.334% |
| Precipio, Inc. | 18.1 Million USD | -990.575% |
| Personalis, Inc. | 225.09 Million USD | 12.303% |
| RadNet, Inc. | 2.88 Billion USD | 93.162% |
| Sera Prognostics, Inc. | 95.44 Million USD | -106.835% |
| Sotera Health Company | 3.13 Billion USD | 93.694% |
| Neuronetics, Inc. | 115.83 Million USD | -70.425% |
| Star Equity Holdings, Inc. | 86.97 Million USD | -126.97% |
| Star Equity Holdings, Inc. | 86.97 Million USD | -126.97% |
| Trinity Biotech plc | 59.43 Million USD | -232.136% |
| T2 Biosystems, Inc. | 34.79 Million USD | -467.305% |
| Twist Bioscience Corporation | 776.4 Million USD | 74.574% |
| Exagen Inc. | 56.94 Million USD | -246.665% |